TNFSF11 and metabolic dysfunction-associated steatotic liver disease: In therapeutic terms, Dmab, an anti-RANKL medication approved for the treatment of osteoporosis, may also prove suitable in the future for the treatment of metabolic diseases, e.g., obesity, T2DM, and NAFLD.